Cite

HARVARD Citation

    Huang, W. et al. (2023). Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer. Bioorganic & medicinal chemistry letters. p. . [Online]. 
  
Back to record